Beyond the direct feedback inhibition of NAMPT, oral NMN intake influences several other regulatory proteins, transporters, and metabolic pathways through both compensatory upregulations and inhibitory downregulations.

### Upregulation of Transporters and Consuming Enzymes

The body adjusts to changing  levels by altering the expression of specialized transporters and the activity of enzymes that utilize :

* **Slc12a8 (NMN Transporter):** In the small intestine, the expression of the  gene is specifically regulated by  levels. During aging or when  levels fall, the body upregulates this transporter to enhance the direct uptake of NMN into cells.
* **Sirtuins and PARPs:** As NMN increases the intracellular  pool, the activity of -dependent enzymes is significantly upregulated. This includes sirtuins (specifically  and ), which regulate metabolic homeostasis, and , which is critical for DNA repair.


* **NRK2 (Nicotinamide Riboside Kinase 2):** While  is the primary enzyme for converting NR to NMN,  exhibits stress-induced upregulation in tissues like injured neurons or stressed cardiac muscle, potentially enhancing the salvage flux when the system is under metabolic strain.



### Upregulation of Excretory and Recycling Pathways

To manage the influx of precursors and the subsequent increase in metabolic byproducts, the body upregulates secondary processing pathways:

* **NNMT (Nicotinamide N-Methyltransferase):** High-dose NMN intake leads to a significant increase in nicotinamide (NAM) as a byproduct of  consumption. To prevent NAM from inhibiting sirtuins, the body upregulates  activity to methylate excess NAM into 1-methylnicotinamide () for excretion.


* **CD38:** This enzyme is a major  consumer whose expression naturally increases with age and chronic inflammation. NMN supplementation can further interact with , as the enzyme also functions as an NMN glycohydrolase, breaking down the supplement before it can be converted to .



### Inhibitory and Regulatory Downregulations

Excessive precursor levels can trigger compensatory downregulations to prevent metabolic over-saturation:

* **Kynurenine (De Novo) Pathway:** The de novo pathway, which synthesizes  from tryptophan, is typically downregulated or remains inactive when systemic  levels are sufficient. High levels of NMN effectively signal that the "salvage" route is meeting the body's needs, reducing the demand for de novo synthesis.


* **Hypothalamic Signaling (Ox2r and Prdm13):** Preclinical evidence suggests that very high doses of NMN (e.g., 300 mg/kg/day) can lead to a downregulation of specific genes in the hypothalamus, such as the orexin type 2 receptor () and . This indicates that excessive supplementation may influence the "NAD World" regulatory network differently than moderate physiological doses.


* **Gut Microbiota Shifts:** Oral NMN inhibits the growth of certain harmful gut bacteria, such as *Fusobacterium* and *Bilophila*, while stimulating the growth of beneficial probiotics like *Akkermansia muciniphila* and *Bacteroides*. This "downregulation" of pathogens contributes to improved intestinal barrier function and reduced systemic inflammation.